Iris-color change developed after topical isopropyl unoprostone treatment

Journal of Glaucoma

Volumn 6, Issue 6, 1997, Pages 430-432

  Yamamoto, Tetsuya ^a   Kitazawa, Yoshiaki ^a  

^a GIFU UNIVERSITY   (Japan)

Author keywords

Iris pigmentation; Isopropyl unoprostone; Latanoprost

Indexed keywords

LATANOPROST; PROSTAGLANDIN; UNOPROSTONE ISOPROPYL ESTER;

ADULT; ARTICLE; CASE REPORT; EYE COLOR; GLAUCOMA; HUMAN; INTRAOCULAR DRUG ADMINISTRATION; IRIS DISEASE; MALE; PRIORITY JOURNAL;

EID: 0031474378     PISSN: 10570829     EISSN: None     Source Type: Journal    
DOI: 10.1097/00061198-199712000-00014     Document Type: Article

References (8)

1. Watson P, Stjernschantz J, the Latanoprost Study Group. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology 1996;103:126-37.
2. Camras CB, The United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. A six-month, masked, multicenter trial in the United States. Ophthalmology 1996;103:138-47.
3. Camras CB, Alm A, Watson P, Stjernschantz J, The Latanoprost Study Groups. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Ophthalmology 1996;103:1916-24.
4. Wistrand PJ, Stjernschantz J, Olsson K. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv Ophthalmol 1997;41(suppl 2):S129-S38.
5. Azuma I, Masuda K, Kitazawa Y, Takase M. Double-masked comparative study of UF-021 and timolol ophthalmic solutions in patients with primary open-angle glaucoma or ocular hypertension. Jpn J Ophthalmol 1993;37:514-25.
6. Yamamoto T, Kitazawa Y, Azuma I, Masuda K. Clinical evaluation of UF-021 (Rescula®; isopropyl unoprostone). Surv Ophthalmol 1997;41(suppl 2):S99-S103.
7. 2α analogue. Adv Prostaglandin Thromboxane Leukotriene Res 1995;23:513-8.
8. Goh Y, Kishino J. Pharmacological characterization of prostaglandin-related ocular hypotensive agents. Jpn J Ophthalmol 1994;38: 236-45.